公开(公告)号：EP0900383B1

公开(公告)日：2003-03-26

申请号：EP97919648.2

申请日：1997-04-23

申请人： SHISEIDO COMPANY LIMITED ,  THE GENERAL HOSPITAL CORPORATION

发明人： MORO, Osamu ,  WAKITA, Kawori ,  HYOCHI, Manami ,  LERNER, Ethan, A. ,  TAJIMA, Masahiro

IPC分类号： G01N33/68 ,  G01N33/567 ,  G01N33/50

CPC分类号： G01N33/6842 ,  A61K38/00 ,  C07K14/47 ,  C07K14/57563 ,  G01N33/68

摘要： This specification relates to use of peptides having a specific affinity to subtype 1 of PACAP (pituitary adenylate cyclase activating polypeptide) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M 65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M 65 acts as an antagonist to PACAP type 1 receptors.

公开(公告)号：EP0900383A1

公开(公告)日：1999-03-10

申请号：EP97919648.0

申请日：1997-04-23

申请人： SHISEIDO COMPANY LIMITED ,  THE GENERAL HOSPITAL CORPORATION

发明人： MORO, Osamu ,  WAKITA, Kawori ,  HYOCHI, Manami ,  LERNER, Ethan, A. ,  TAJIMA, Masahiro

IPC分类号： G01N33 ,  A61K38 ,  C07K14

CPC分类号： G01N33/6842 ,  A61K38/00 ,  C07K14/47 ,  C07K14/57563 ,  G01N33/68

摘要： This specification relates to use of peptides having a specific affinity to subtype 1 of PACAP (pituitary adenylate cyclase activating polypeptide) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M 65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M 65 acts as an antagonist to PACAP type 1 receptors.

公开(公告)号：EP2011883A1

公开(公告)日：2009-01-07

申请号：EP07742776.3

申请日：2007-04-24

申请人： Shiseido Company, Limited

发明人： AOKI, Hirofumi ,  KISHIMOTO, Jiro ,  MORO, Osamu

IPC分类号： C12Q1/68 ,  A61K45/00 ,  A61P17/16 ,  C12N15/09 ,  G01N33/15 ,  G01N33/50

CPC分类号： C12Q1/6883 ,  C12Q2600/148 ,  C12Q2600/158 ,  G01N33/5088

摘要： The present invention provides a skin test method for predicting the formation of spots in the skin. This method is characterized by judging skin to be susceptible to spot formation in the case expression of genes consisting of MLSTD1, MOGAT1, FADS2, FADS1, HSD3B1, ELOVL3, BG1, PECR, FABP7, FA2H, HAO2, ALOX15B, PDE6A, LZTS1, SEC14L4, BAMBI, CIDEA, TERE1, GAL, THRSP, INSIG1 or CUTL2 in the epidermis is accelerated, or the expression of genes consisting of RBBP6, MSMB, WIF1, ANKRD12, FLG, SYNE2, SCEL, NKTR or AMBP in the epidermis is decreased as compared with normal expression in the epidermis.

摘要翻译： 本发明提供用于预知皮肤斑形成的皮肤检查方法。 这种方法是通过判断皮肤易受在基因由......组成MLSTD1，MOGAT1，FADS2 FADS1，HSD3B1，ELOVL3，BG1，PECR，FABP7，FA2H，HAO2，ALOX15B，PDE6A，LZTS1，SEC14L4的情况下表达点形成为特征的 ，BAMBI，CIDEA，TERE1，GAL，THRSP，INSIG1或CUTL2在表皮被加速，或基因在表皮RBBP6，MSMB，WIF1，ANKRD12，FLG，SYNE2，SCEL，NKTR或AMBP由......组成的减小作为表达 与在表皮正常表达进行比较。